Skip to content

EBIT at other companies

Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-$39.62M-21.1%
Opko Health logo
Opko HealthOPK
-$51.02M+24.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.93M+27.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.91M-427%
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%
CapEx-
Free cash flow-$34.5M-27.8%

Valuation

See full
Market cap$973.05M+244%
Enterprise value$921.46M+295%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0.0×
Current ratio10.9×-4.3×

Where this comes from

Calculated from Olema Pharmaceuticals, Inc.’s reported figures.

The official record: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Olema Pharmaceuticals, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Olema Pharmaceuticals, Inc.'s EBIT?
Olema Pharmaceuticals, Inc. (OLMA) reported EBIT of -$57.99M in Q1 2026.
How has Olema Pharmaceuticals, Inc.'s EBIT changed year-over-year?
Olema Pharmaceuticals, Inc.'s EBIT decreased by 66.3% year-over-year, from -$34.87M to -$57.99M.
What is the long-term trend for Olema Pharmaceuticals, Inc.'s EBIT?
Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s EBIT has grown at a 25.7% compound annual growth rate (CAGR), from -$71.49M to -$178.7M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.